: ,
Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Clinical Trials Key Takeaways Retatrutide, a new triple receptor agonist, appears particularly promising as a non-diabetic weight loss agent because it targets glucagon, GLP-1, and GIP
Some approved and experimental weight loss drugs Wegovy from Novo Nordisk: Approved weekly injection that activates GLP-1 Zepbound from Eli Lilly: Approved weekly injection that activates GLP-1 and GIP Saxenda from Novo Nordisk: Approved weekly injection that activates GLP-1 MariTide from Amgen: Experimental monthly injection that activates GLP-1 and blocks GIP Danuglipron from Pfizer: Experimental once-daily pill that activates GLP-1 VK2735 from Viking Therapeutics: Experimental weekly injection that activates GLP-1 and GIP Pemvidutide from Altimmune: Experimental weekly injection that activates GLP-1 and another gut hormone called glucagon GSBR-1290 from Structure Therapeutics: Experimental weekly pill that activates GLP-1 Survodutide from Zealand Pharma, Boehringer Ingelheim: Experimental weekly injection that activates GLP-1 and glucagon That appears to contradict how Zepbound works
This lack of motility, the muscle movements within your GI tract that move food forward through the digestive process, causes nausea, vomiting, and premature fullness
4.5 Regulatory Status Hexarelin has: No FDA-approved medical indications No human-use approvals in any jurisdiction Availability only as a research compound It is on the WADA prohibited substances list Dosing Protocols For complete community dosing protocols, reconstitution instructions, cycling strategies, and desensitization management, see our dedicated guide: Hexarelin Dosing Guide: Community Protocols, Reconstitution & Cycling 6
